This article has Open Peer Review reports available.
Integrative analysis of neuroblastoma and pheochromocytoma genomics data
© Szabo et al.; licensee BioMed Central Ltd. 2012
Received: 8 March 2012
Accepted: 26 October 2012
Published: 29 October 2012
Pheochromocytoma and neuroblastoma are the most common neural crest-derived tumors in adults and children, respectively. We have performed a large-scale in silico analysis of altogether 1784 neuroblastoma and 531 pheochromocytoma samples to establish similarities and differences using analysis of mRNA and microRNA expression, chromosome aberrations and a novel bioinformatics analysis based on cooperative game theory.
Datasets obtained from Gene Expression Omnibus and ArrayExpress have been subjected to a complex bioinformatics analysis using GeneSpring, Gene Set Enrichment Analysis, Ingenuity Pathway Analysis and own software.
Comparison of neuroblastoma and pheochromocytoma with other tumors revealed the overexpression of genes involved in development of noradrenergic cells. Among these, the significance of paired-like homeobox 2b in pheochromocytoma has not been reported previously. The analysis of similar expression patterns in neuroblastoma and pheochromocytoma revealed the same anti-apoptotic strategies in these tumors. Cancer regulation by stathmin turned out to be the major difference between pheochromocytoma and neuroblastoma. Underexpression of genes involved in neuronal cell-cell interactions was observed in unfavorable neuroblastoma. By the comparison of hypoxia- and Ras-associated pheochromocytoma, we have found that enhanced insulin like growth factor 1 signaling may be responsible for the activation of Src homology 2 domain containing transforming protein 1, the main co-factor of RET. Hypoxia induced factor 1α and vascular endothelial growth factor signaling included the most prominent gene expression changes between von Hippel-Lindau- and multiple endocrine neoplasia type 2A-associated pheochromocytoma.
These pathways include previously undescribed pathomechanisms of neuroblastoma and pheochromocytoma and associated gene products may serve as diagnostic markers and therapeutic targets.
Neuroblastoma (NB) and pheochromocytoma (PCC) are neural crest-derived tumors that are both associated with significant morbidity and mortality.
NB is the most frequent malignant tumor in children accounting for 15% of childhood cancer mortality. Approximately 38% of primary tumors are localized in the adrenal medulla and 1-2% of newly diagnosed NB cases are related to familial history of disease . The genetic aberration most consistently associated with poor outcome in NB is the amplification of v-myc myelocytomatosis viral related oncogene (MYCN), which occurs in 20% of primary tumors. Chromosomal aberrations as deletion of chromosomes 1p, 11q and gain of 17q are also associated with poor prognosis. The International Neuroblastoma Staging System is most commonly used for NB staging. Stages 1 and 2 represent localized primary tumors, whereas the primary tumor is unresectable in stage 3 with or without lymph node infiltration, and stage 4 represents any primary tumor with dissemination to distant lymph nodes, bone marrow, liver, skin or other organs. The special 4S phenotype is characterized by localized tumor in infants younger than 1 year, with dissemination limited to skin, liver, or bone marrow, and mostly spontaneous regression .
PCC is a rare tumor, mostly occurring in adults and in the adrenals. Approximately 10% of PCC are malignant. PCC mostly develops in the adrenal. Extraadrenal PCC is termed paraganglioma (PGL). 25–30% of all cases are related to monogenic hereditary tumor syndromes including multiple endocrine neoplasia 2 (MEN2), von Hippel-Lindau syndrome (VHL), neurofibromatosis type 1 (NF1) and the group of PGL syndromes caused by mutations in genes encoding succinate dehydrogenase (SDH) subunits and associated factors [2, 3]. Novel genes like TMEM127 and MAX have also been described [4, 5]. Two major pathogenic pathways have been established in these syndromes: hypoxia pathway (VHL and PGL syndromes) and the pathway involving Ras and mechanistic target of rapamycin (mTOR) activation (MEN2 and NF1). These pathways seem to be implicated in the pathogenesis of sporadic PCC, as well [5, 6].
Despite many data on these tumors, we are still far from an overall picture on tumorigenesis. Several studies applying functional genomics approaches have been performed on these tumors to date including the analysis of mRNA and microRNA expression patterns, and studies on chromosome aberrations. In silico analysis of functional genomics studies might be a useful way to decipher common pathogenic pathways and differences .
In this study, we have performed a large scale in silico analysis of functional genomics data including a large number of NB and PCC samples to establish their similarities, differences, and to compare their different subgroups using analysis of gene expression, microRNA expression and their potential mRNA targets, and chromosome aberrations. For this purpose, we have applied GeneSpring, Gene Set Enrichment Analysis (GSEA), and Ingenuity Pathway Analysis (IPA) software. We have also applied a novel bioinformatical analysis based on cooperative game theory for the establishment of relevant gene expression changes. In this approach developed by Moretti et al. , genes serve as players and microarray measurements are called cooperative games. By the cooperative game theory analysis we are able to identify the power or relevance index of each gene in inducing the investigated pathological state.
Characteristics of the analyzed NB microarray data sets
Łastowska et al., 2007 
Affymetrix HG-U133 Plus 2.0 Array
Stage 1: 4, Stage 2: 2, Stage 3: 1, Stage 4: 20, Stage 4S: 3
MYCN-amplified: 10, MYC-non-amplified: 20
Hiyama et al., 2004 
Stage 1: 21, Stage 2: 6, Stage 3: 5, Stage 4: 13, Stage 4S: 6
MYCN-amplified: 7, MYC-non-amplified: 44
Janoueix-Lerosey et al., 2008 
52 neuroblastoma, 8 ganglioneuroblastoma, 3 ganglioneuroma, 1 unknown
Stage 1: 10, Stage 2: 10, Stage 3: 7, Stage 4: 16, Stage 4S: 8, unknown: 1
MYCN-amplified: 14, MYC-non-amplified: 32, unknown: 6
Wilzén et al., 2009 
Affymetrix HG-U133A Array
Stage 1: 1, Stage 2: 1, Stage 3: 4
De Preter et al., 2006 
18 neuroblastoma, 3 adrenal cortex, 3 adrenal neuroblast
Stage 1: 4, Stage 3: 3, Stage 4: 10, Stage 4S: 1
MYCN-amplified: 5, MYCN-non-amplified: 13
Albino et al., 2008 
10 neuroblastoma, 3 ganglioneuroblastoma, 6 ganglioneuroma, 9 microdissected tumors
Staege et al., 2004 
5 neuroblastoma, 5 Ewing family tumor
Stage 1: 3, Stage 3: 1, Stage 4: 1
Wang et al., 2006 
Affymetrix HG-U95 Version 2 Array
101 neuroblastoma, 1 fetal brain
Stage 1: 28, Stage 3: 23, Stage 4: 50
MYCN-amplified: 20, MYCN-non-amplified: 81
Characteristics of the analyzed PCC microarray data sets
Burnichon et al., 2011 
Affymetrix HG-U133 Plus 2.0 Array
Sporadic: 95, MEN2A: 9, SDHA: 1, SDHB: 17, SDHC: 2, SDHD: 3, VHL: 27, NF1: 9, Other: 25
Qin et al., 2010 
Affymetrix HG-U133A Array
Sporadic: 35, MEN2A: 9, SDHB: 10, SDHD: 2, VHL: 6, NF1: 2, Other: 11
Qin et al., 2010 
Affymetrix HG-U133A 2.0 Array
Sporadic: 36, MEN2A: 3, MEN2B:1, SDHB: 4, VHL: 3, NF1: 2, Other: 1
Hensen et al., 2009 
Affymetrix HG-U95 Version 2 Array
Sporadic: 7, SDHD: 6, PGL2: 4
Characteristics of the datasets used for cluster analysis
Henderson et al., 2005 
4 alveolar rhabdomyosarcoma, 5 chondroblastoma, 4 chondromyxoid fibroma, 7 chondrosarcoma, 4 chondroma, 3 dedifferentiated chondrosarcoma, 3 embryonal rhabdomyosarcoma, 5 Ewing tumor, 5 fibromatosis, 8 leiomyosarcoma, 3 lipoma, 4 malignant peripheral nerve sheath tumor, 10 monophasic synovial sarcoma, 7 myxoid liposarcoma, 4 neurofibroma, 11 osteosarcoma, 3 sarcoma, 4 schwannoma, 3 well-differentiated liposarcoma
Giordano et al., 2006 
4 anaplastic thyroid carcinoma, 10 follicular thyroid adenoma, 2 follicular thyroid carcinoma, 2 medullary thyroid carcinoma, 4 normal thyroid, 7 oncocytic thyroid adenoma, 8 oncocytic thyroid carcinoma, 13 papillary thyroid carcinoma
Freije et al., 2004 
6 astrocytoma, 10 glioblastoma, 5 anaplastic mixed oligo-astrocytoma, 10 anaplastic oligodendroglioma
Tirode et al., 2007 
11 Ewing tumor
Jones et al., 2005 
6 chromophobe RCC, 10 clear cell RCC, 10 oncocytoma, 10 papillary RCC, 8 transitional cell carcinoma
Lenburg et al., 2003 
16 clear cell RCC, 1 normal kidney
De Preter et al., 2006 
3 adrenal cortex, 3 neuroblast
Albino et al., 2008 
3 ganglioneuroblastoma, 6 ganglioneuroma
Boyault et al., 2007 
17 hepatocellular carcinoma, 3 hepatocellular adenoma
Parent et al., 2008 
4 hypothalamic hamartoma
Wong et al., 2005 
5 juvenile pilocytic astrocytoma, 3 normal cerebellar tissue, 2 normal fetal brain
Su et al., 2007 
1 large cell lung carcinoma, 14 lung adenocarcinoma, 12 normal lung
Monzon et al., 2009 
1 medullary thyroid carcinoma
Harlin et al., 2009 
Salomon et al.,*
Corbin et al., 2009 
9 normal kidney, 11 Wilms' tumor
Mangiola et al.,*
3 normal white matter
Characteristics of gene sets in publications where whole microarray data were unavailable
Number and distribution of samples
Asgharzadeh et al., 2006 
55 gene model for the prediction of high molecular risk NB
Berwanger et al., 2002 
Stage 1: 19, stage 4: 21 NB
36 genes differently expressed between stage 1 and stage 4 NB
Fischer et al., 2010 
81 unfavorable, 8 favorable NB, without 11q aberration
163 genes differently expressed between favorable and unfavorable NB
Oberthuer et al., 2006 
251 NB, among these 77 was used to construction of a gene expression–based classifier and 177 to validate it
60 genes with higher than 2-fold expression changes from 144 gene predictor of favorable and unfavorable NB
Oberthuer et al., 2007 
79 favorable and 48 unfavorable NB
5 genes with higher than 2-fold expression changes from 349 gene predictor of favorable and unfavorable NB
Ohira et al., 2005 
41 top-ranked genes used for prediction of 2 year and 5 year prognosis of NB
Schramm et al., 2005 
59 MYCN-non-amplified, 9 MYCN-amplified NB
28 top-ranked genes to discriminate MYCN-non-amplified and MYCN-amplified NB
Stage 1: 20, stage 2: 16, stage 3:7, stage 4: 15, stage 4S: 10 NB
30 top-ranked genes to discriminate stage 1–2 and stage 3–4 NB
22 top-ranked genes to discriminate stage 4S and stage 4 NB
Takita et al., 2004 
stage 1: 9, stage 2: 4, stage 4: 6, stage 4S: 1 NB
60 top-ranked genes to discriminate stage 1–2 and stage 4 NB
Thorell et al., 2009 
16 favorable and 15 unfavorable NB
81 genes differently expressed between favorable and unfavorable NB, validated by QRT-PCR
Vermeulen et al., 2009 
59 prognostic genes for high risk NB
Brown et al., 2008 
12 MEN2A, 11 VHL PCC
17 genes differently expressed between MEN2A and VHL by SAM (fold change: 2-fold, delta lower than 0.05)
Eisenhofer et al., 2004 
7 MEN2A, 12 VHL PCC
493 genes differently expressed between MEN2A and VHL PCC
Eisenhofer et al., 2008 
32 MEN2A, 47 VHL PCC
42 selected pathway components differently expressed between MEN2A and VHL PCC
Huynh et al., 2006 
13 MEN2A, 18 VHL PCC
15 genes selected differently expressed genes between MEN2A and VHL PCC
López-Jiménez et al., 2010 
8 SDHB, 1 SDHC, 4 SDHD, 15 VHL, 17 RET, 4 NF1
444 genes differently expressed between VHL/SDH and RET/NF1 PCC
Analysis of raw microRNA expression data was possible in both NB and PCC. MicroRNA data for NB were obtained from the study of Schulte et al.  including intensity values of 307 microRNAs in 69 samples. To identify differences in microRNA expression between these groups, one-way ANOVA with Scheffé’s post hoc test was used. Statistical analysis was performed by Statistica 8 software (StatSoft Inc., Tulsa, OK, USA). For the analysis of microRNA targets in PCC, we have used our previously published data .
Altogether we have analyzed gene expression data from 1784 NB and 531 PCC tissues in our in silico analysis.
Statistical analysis of mRNA profiling studies
For the classification of tumors, hierarchical clustering was performed on the average of samples within the groups by calculating Euclidean, Squared Euclidean, Manhattan, Differential, Chebyshev distance metric and using the averaged linkage rule. Cluster analysis and all subsequent statistical analyses were performed by Genespring GX 10.5 software (Agilent Tech Inc., Santa Clara, CA, USA).
Identification of gene sets differentially expressed between NB, PCC and other tissues, different stages of NB and different PCC subtypes was carried out by one-way ANOVA. Each ANOVA was followed by Tukey’s post hoc test for all pairwise multiple comparisons. Unpaired t-test was used for the comparison of MYCN-amplifying, non-amplifying and VHL/SDH-, MEN2/NF1- related PCC. Fold change filter was set to 2-fold in each comparison. Furthermore, Benjamini-Hochberg multiple testing correction (corrected p<0.05) was performed to minimize false positive cases.
Search for similarities between NB and PCC mRNA expression patterns
To identify genes with highly similar expression levels between NB and PCC samples, we have used the criteria established by Cheng et al.  for the identification of reference genes: i., raw intensity value is higher than 20 percent in at least 80% of samples in each group. ii., coefficient of variation is lower than 0.3, and iii. fold change is lower than 1.2. Genes previously identified by Cheng et al.  as reference (housekeeping) genes in 4804 samples from 13 different tissues including normal and tumor samples have been filtered out from gene lists. The remaining genes were loaded into Ingenuity Pathway Analysis (IPA). The reference gene selection was performed by an own software written in Java program language.
Cooperative game theory-based analysis of microarray studies
The main goal of cooperative game theory analysis on microarray samples is the investigation of gene involvement in disease pathogenesis based on a mathematical model. In this analysis, it is initially hypothesized that all genes with more than two-fold expression changes between an investigated sample and the reference sample set play equal role in the pathogenesis, as their cooperation results in a different status. Next, the most frequently involved (playing) genes are searched for. By this approach we are able to identify the most relevant genes (players) in the pathogenesis, because the calculated subsets of genes usually act (change their expression) cooperatively .
To calculate the relevance index of genes we have used the same procedure as Albino et al. . We have generated Boolean matrices where the columns represented the samples (games) and the rows represented the genes (players). The values of the matrices were set to 1 if the expression of the gene in the given sample was higher than 2-fold compared to the other group and 0 if not. Shapley values  for each gene were calculated as we divided each value in the columns of the Boolean matrices by the sum of the given column and averaged these values by the rows. Finally, each Shapley value was divided by the highest one. We performed these calculations vice versa between the compared groups and genes with values higher than 0.6 in both calculations were selected for further analysis. Gene sets generated by this approach were loaded into IPA. Calculations were performed by an own program written in Java program language.
Gene set enrichment analysis (GSEA)
GSEA analyzes gene expression data and determines whether a particular set of genes is over- or underrepresented in the samples compared . GSEA was performed by GSEA software v2.0 (http://www.broad.mit.edu) in pairwise comparisons of NB versus PCC, different stages of NB, MYCN-non-amplifying vs. MYCN-amplifying NB, SDH/VHL vs. MEN2/NF1 PCC and MEN2A vs. VHL-associated PCC. Gene expression results derived from microarray experiments were correlated with chromosomal data and microRNA gene sets. GSEA was performed using gene set permutation type as default and the number of permutation was set to 1000. Statistical significance levels were defined as nominal p-value 0.05 and false discovery rate 0.25.
Correlation of GSEA results retrieved from publicly available microarray data with cytogenetic changes
To correlate gene expression changes to chromosomal aberrations we have compared significantly enriched chromosomal gene sets by GSEA with the list of previously published chromosomal aberrations for the given tumor types. From the gene lists of these overlapping chromosomal regions, we have selected the most prominent expression changes by Leading Edge Analysis (LEA) using GSEA software v2.0 (http://www.broad.mit.edu). The leading edge subset of genes can be defined as the core accounting for the enrichment signal of the significant chromosomal gene set. This method has been described in our previous study  and defined strict cut-off parameters to identify genes harbored on aberrant chromosome regions showing the most prominent expression changes .
Correlation of GSEA results retrieved from publicly available microarray data with microRNA expression
Identification of predicted microRNA targets was performed using TargetScan 5.2 (http://www.targetscan.org), PicTar (http://pictar.org) and MicroCosm Targets (http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/) databases. The outputs from these databases were merged by an own program written in C++ program language.
Further analysis aimed at tissue specific microRNA target prediction has been performed as described in our previous study . Briefly, unexpressed mRNAs (intensity value is lower than 20 percentile in at least 20 percent of the samples in both groups) were filtered out from target lists. For all significantly differentially expressed microRNAs within the two groups, we have generated gene sets from their expressed target genes. Then GSEA was performed and LEA was used to select potential mRNA targets with inverse expression alterations as their regulatory microRNAs. Pairwise comparison was performed between different stages and MYCN-non-amplifying and amplifying NB and between SDH/VHL- and MEN2/NF1- and MEN2A-, VHL-related PCC. All analyses were performed by own programs written in Java program language.
We have used Ingenuity Pathway Analysis (IPA) to decipher the possible biological relevance of gene expression changes established. (Ingenuity Systems, http://www.ingenuity.com; Redwood City, CA, USA). Gene sets established both by in silico analysis of mRNA expression (significant expression changes, unchanged expression, results of cooperative game theory analysis and data collected by literature search), GSEA of microRNA and comparative genomic hybridization (CGH) gene sets were subjected to IPA and significant pathways (p<0.05) were compared to each other.
We have performed several analyses including a taxonomical analysis based on the gene expression profile of NB and PCC samples and other tissues, and tried to characterize the most prominent differences between neural crest-derived tumors and other tissues. We have compared NB and PCC data to establish their differences and similarities, moreover within the NB and PCC groups, data from different NB stages and from PCC subgroups, respectively, have been analyzed (Additional file 1).
Differences between NB, PCC and other tumors and similarities of NB and PCC tissues
By the comparison of NB or PCC groups with the investigated 54 normal tissues and tumor types, we have identified 36 genes significantly differentially expressed in more than 80% of comparisons (Additional file 2). By the manual inspection of these 36 genes, they could be clearly categorized as genes involved in catecholamine synthesis, transport and storage: dopamine beta-hydroxylase (DBH), tyrosine hydroxylase (TH), chromogranin A (CHGA), chromogranin B (CHGB), solute carrier family 6 member 2 (SLC6A2), solute carrier family 18 member 1 (SLC18A1), and transcription factors and homeobox genes involved in neural crest-derived cell development: paired-like homeobox 2a and 2b (PHOX2A, PHOX2B), GATA binding protein 2 and 3 (GATA2, GATA3), heart and neural crest derivatives expressed 2 (HAND2).
To identify genes responsible for the similarities of NB and PCC gene expression patterns, we have searched for genes expressed in both tumors with the lowest fold change and variation. The previously published  reference (or housekeeping) genes were filtered out from these gene lists to select genes with unchanged expression specifically between NB and PCC. The analysis was performed on three different platforms. By this approach we have identified 62 genes that were common in at least two comparisons (Additional file 3). By IPA of these gene sets, death receptor signaling was the most significant common pathway in each comparison.
Differences between NB and PCC tissues
The comparison of NB and PCC was possible on three platforms, and by the comparison of these gene lists we have identified 758 common expression changes in at least two comparisons (Additional file 4), for example: anaplastic lymphoma receptor tyrosine kinase (ALK), neurotrophic tyrosine kinase, receptor, type 3 (NTRK3), tubulin, beta 2A-C, 3 (TUBB2A, TUBB2B, TUBB2C, TUBB3). By IPA, cancer regulation by stathmin1 has been identified as the most significant pathway between PCC and NB.
Expression changes between different subgroups of NB
The comparison of significant gene lists between stages 1 and 4 was possible on three different platforms. Within these, we have found 28 common expression changes in at least two studies (Additional file 5). The comparison of stage 4S and stage 4 NB was possible on one platform. The list of significantly differentially expressed genes was compared to the gene list reported by Schramm et al.  and 5 common genes have been found in both, for example: aldehyde dehydrogenase 3 family member A2 (ALDH3A2) and phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) (Additional file 5).
The analysis of gene expression profiles of MYCN-non-amplifying and MYCN-amplifying NB was possible on three platforms. The comparison of these revealed 259 common significant expression changes in at least two studies. To identify the most reliable expression changes, we intersected this gene set with a further one, reported by Schramm et al. . By this approach, we have identified nine genes with significant expression changes that were common in all four gene sets, for example: DEAD box polypeptide 1 (DDX1), MYCN, ornithine decarboxylase 1 (ODC1), transketolase (TKT) (Additional file 5).
By the comparison of gene lists revealed from the statistical analysis of early versus late stage, MYCN-non-amplifying versus MYCN-amplifying and favorable versus unfavorable NB samples and from the literature search, we have found 519 genes that were reported at least twice in these gene lists (Additional file 5). Among these, the most prevalent genes were: NTRK1, MYCN, secretogranin II (SCG2), pleiotrophin (PTN), neuronal cell adhesion molecule (NRCAM) and ODC1. The IPA of significant gene expression changes, cooperative game theory analysis, chromosomal changes and microRNA affected genes revealed the axonal guidance as the most significant pathway in the pathogenesis of unfavorable NB.
Significant expression changes between VHL/SDH and MEN2/NF1 PCC
The comparison of VHL/SDH- and MEN2/NF1-associated PCC was possible on three platforms. To generate a more reliable dataset of significant expression changes, we supplemented these gene lists with a further one, found by literature search . By this approach, we have identified 240 common significant gene expression changes in at least two gene lists (Additional file 6), and among these 9 were common in all four comparisons, for example: phenylethanolamine N-methyltransferase (PNMT), ret proto-oncogene (RET), Src homology 2 domain containing transforming protein 1 (SHC1). By IPA, IGF1 (insulin-like growth factor 1) signaling turned out to be the most significantly influenced pathogenic pathway between SDH/VHL and MEN2/NF1 PCC.
Significant expression changes between MEN2A and VHL PCC
The comparison of MEN2A- and VHL-associated PCC was possible on three platforms, and a further dataset was analyzed by SAM (significance analysis of microarrays), moreover three significant gene lists were collected from literature search. By the comparison of these seven gene lists, we have identified 162 genes which were common in at least two gene lists, for example: CHGB, neural cell adhesion molecule 1 (NCAM1), placental growth factor (PGF), PNMT, vascular endothelial growth factor (VEGF) (Additional file 7). By the IPA of significant gene expression changes, cooperative game theory analysis, chromosomal aberrations and microRNA affected genes, the most significant pathogenic pathway was VEGF and hypoxia inducible factor 1 alpha (HIF1-α) signaling.
Cooperative game theory analysis
The number of index genes revealed from cooperative game theory analysis  was similar to the number of significant gene expression changes and showed good overlap with them. In average, more than 40% of significant gene expression changes were identified as index genes by cooperative game theory analysis in different comparisons. The pathway analysis of index genes always revealed the same canonical pathways as significant gene lists and supplemented these with several new members. These observations support the applicability of cooperative game theory in the in silico analysis of gene expression.
Comparison of NB and PCC with other tumors
By the cluster analysis of different tumors and normal tissues, we have found that NB and PCC tissues are more similar to each other than to any other tumor entity. This observation is not surprising, as both NB and PCC are neural crest-derived tumors (Figure 1).
The homeobox transcription factor PHOX2B is essential for the differentiation and maintenance of noradrenergic neurons . PHOX2B mutations are observed in rare hereditary forms of NB and Hirschsprung’s disease . PHOX2B is involved in the transcriptional regulation of RET expression , however mutations of PHOX2B in hereditary and sporadic PCC have not been reported, yet.
The downstream targets of the master regulators of neural crest-derived precursor cell development PHOX2B and HAND2 are PHOX2A, GATA2, GATA3. These transcription factors play important roles in the expressional regulation of the TH and DBH genes . TH catalyzes the rate limiting step of NA production, and DBH converts dopamine to NA. NA in chromaffin cells is co-stored in secretory granules with CGA and CGB molecules. The uptake into granules is mediated by SLC18A1 protein from the cytoplasm and by SLC6A2 from the extracellular space .
By the comparison of NB or PCC tissues with other tumors and normal tissues, we have found the significant overexpression of all the above mentioned genes in NB or PCC samples in more than 90 comparisons. This observation highlights the common origin of NB and PCC, however, it is surprising that there are only very few data on the expression of these genes in PCC.
Similarities between NB and PCC
Avoidance of apoptosis is a key process of tumorigenesis. Since this pathway included the most similar gene expression patterns in NB and PCC, we may conclude that these tumors may use the same strategies for rescue from programmed cell death.
The importance of proteins involved in the regulation of apoptosis triggered by death receptors (DRs) has been already reported in NB. Apoptosis in mammalian cells can be initiated through two major pathways: one involving tumor necrosis factor alpha (TNFα) and DR1-6, the other involving release of cytochrome c from mitochondria through Fas activation .
Numerous reports underline the significance of mitochondria-dependent signaling in NB. Fas resistance in NB may develop by the inactivation of caspase 8, which is absent in more than one third of NB cases , and often methylated in more than 60% of PCC . Fas resistance may even develop in caspase 8-expressing NB via high level expression of the antiapoptotic protein BCL2 . In the rat pheochromocytoma PC12 cell line, BCL2 overexpression inhibits apoptosis . We have found very similar expression levels of BCL2 in the investigated NB and PCC tissues. Further members of mitochondria-dependent signaling were also similar between NB and PCC including Fas-associated via death domain (FADD), HtrA serine peptidase 2 (HTRA2), heat shock 27kDa protein 2 (HSPB2). These similarities raise the possible involvement of BCL2-mediated Fas resistance and mitochondria-dependent apoptotic pathway in PCCs pathogenesis, as well.
Underexpression of death receptor 3 (TNFRSF15) in NB has been reported previously, and correlated with the frequent deletion of chromosome region 1p36  which chromosomal aberration is also known in sporadic and MEN2A-associated PCC . The expression of DR3 has been very similar in NB and PCC in our analysis.
Differences of NB and PCC
Phosphorylation of stathmin 1 at the beginning of mitosis is pivotal for allowing microtubules to polymerize and assemble into a mitotic spindle, whereas its dephosphorylation by protein phosphatases (PPIs) is critical for cells to exit mitosis. A similar effect is also shown by taxanes and vinca alkaloids, used for the chemotherapy of several cancers including NB .
By the comparison of NB and PCC, we have observed mainly the overexpression of genes involved in stathmin phosphorylation and dephosphorylation, tubulins and stathmin 1 in NB. These changes may highlight important differences in cell cycle regulation and chemoresistance between benign PCC and malignant NB via the enhanced regulation of stathmin function.
Differences between early, late stage, MYCN-amplifying, non-amplifying NB
Neuronal connections are formed by migrating axons, and the growth edge contains receptors which help to navigate the axon to its final destination. Several attractive and repulsive guidance cues and receptors have been identified for example roundabout 1 (ROBO1), plexin, neurophilin, ephrin (EFN) and neurotrophic tyrosine kinase (NTRK) receptors .
Among the receptors involved in axonal guidance, the underexpression of NTRK1 (TrkA) was the most common (observed in more than ten datasets) alteration in MYCN-amplifying and unfavorable NB (Figure 5). We have also observed the underexpression of NTRK3 (TrkC) in three cases and the overexpression of NTRK2 (TrkB) in one. High NTRK1 and NTRK3 and low NTRK2 expression in NB was associated with favorable clinical features and inversely associated with MYCN amplification . Among downstream members of NTRK signaling, we have also observed the underexpression of PIK3R1 in eight, PIK3C3 in two, PLCB1 and PLCD4 in 1–1 dataset in late stage, MYCN-amplifying and unfavorable NB. The underexpression of PIK3R1 was correlated with the overexpression of microRNAs hsa-miR-105, hsa-miR-181a, hsa-miR-181d and hsa-miR-383 in these cases and it was a very frequent expression change in our in silico analysis, however, its significance in NB pathogenesis has not been described yet.
Significant expressional alterations of other receptors involved in neuronal migration were also observed. Underexpression of plexin receptor C1 (PLXNC1), a receptor characterized as a tumor suppressor in melanoma  was observed in late stage and MYCN-amplifying NB in seven cases (Figure 6). The underexpression of EFNB2 and EFNB3 was observed in two, and the underexpression of ephrin receptor A5 (EPHA5) in five datasets between early and late stage, and MYCN-non-amplifying and amplifying NB, respectively (Figure 7).
Neurophilin-1 (NRP1) receptor is involved in neuronal development and angiogenesis; and it binds semphorin3 proteins and VEGF. Significant downregulation of NRP1 in late stage and MYCN-amplifying NB was noted in five datasets, and downregulation of NRP1 in these cases was correlated with the overexpression of hsa-miR-214 (Figure 6).
In our in silico analysis, we have observed several novel gene expression changes. The expressional alterations of axonal guidance pathway may be important in the development of NB metastases via the disintegration of cell-cell connections and highlight some potential therapeutic targets in unfavorable cases.
Differences between SDH/VHL-, MEN2/NF1-related PCC
The IGF1 receptor (IGF1R) is a transmembrane tyrosine kinase protein. The activated IGF1R phosphorylates SHC, which binds to RET and growth factor receptor-bound protein 2 (GRB2), leading to activation of RAS-MAPK signaling. Previous studies confirmed that SHC binding to RET is crucial for the transforming activity of RET mutant proteins . The enhanced IGF-1 signaling in RET-related PCC may be an important parallel pathway in the pathogenesis, which leads to the activation of RET via SHC. In MEN2/NF1-related PCC, downregulation of IGFBP3 and IGFBP7 was observed in two studies and the downregulation of IGFBP4 and IGFBP5 was correlated with the overexpression of hsa-miR-132 and has-miR-885-5p. The overexpression of IFG1R in MEN2/NF1-related PCC was observed in two studies.
The overexpression of SHC1 and RET was observed in all four comparisons in MEN2/NF1-related PCC. We have also observed the overexpression of C-FOS in these tumors as a possible outcome of the enhanced signaling activities of SHC/GRB/RAS complexes. Furthermore, the overexpression of HRAS and RRAS2 was correlated with the frequent loss of chromosome region 11p15 in VHL PCC .
Differences between MEN2A- and VHL -related PCC
HIF1-α is a transcription factor that transactivates genes participating in responses to hypoxia . VHL is involved in the degradation of HIF1-α protein. Under normoxia, EGL nine homolog (EGLN) proteins are activated and hydroxylate HIF1-α, which allows VHL protein to bind and ubiquitinate HIF.
By the comparison of MEN2A- and VHL-related PCC, we have observed the significant overexpression of EGLN3 in two studies and the overexpression of EGLN1 was correlated with the downregulation of hsa-miR-132 in VHL PCC. These gene expression changes may lead to enhanced hydroxylation of HIF1-α. The overexpression of HIF1-α target genes was also observed in VHL PCC as matrix metalloproteinase 2 (MMP2) and glucose transporter GLUT1. GLUT1 overexpression in VHL could be correlated with the frequent loss of chromosome 1p34 often observed in MEN2A PCC . Immunohistochemical analysis of GLUT1, however, failed to detect the protein in chromaffin cells . The overexpression of MMP2 was reported previously in several cancer tissues, and the inhibition of MMP2 function by halofuginone resulted in significant reduction of vascular functionality, decreased vascular density and less tumor size in VHL PCC in vivo models .
The overexpression of two VEGF genes, VEGFA and placental growth factor (PGF) were observed in three independent studies in VHL-related PCC. Overexpression of PGF was observed in several cancers. Reduced vascularisation and size of tumors were observed in PGF deficient mice ; however, its effect on tumor growth and angiogenesis is controversial. Binding of PGF to VEGFR1 leads to crosstalk between VEGFR1 and VEGFR2 and enhances VEGF-driven VEGFR2 signaling. PGF forms heterodimers with VEGF that do not display significant angiogenic effects, reducing the formation of VEGF-VEGF homodimers and lacks the ability of to induce angiogenesis by VEGFR2 activation .
The significance of HIF1-α and VEGF signaling is well characterized in VHL PCC, and our results may support and supplement these previous findings. Furthermore, these data corroborate the significance and authenticity of our in silico analysis results.
The integration of different data sources from the same entities is one of the greatest challenges in contemporary molecular biology. We have applied several bioinformatics approaches to compare and integrate the genetic and transcriptional data from NB and PCC. We have demonstrated the usefulness of reference gene analysis for the identification of similarities among different entities and cooperative game theory analysis as a good method for the supplementation of results by conventional statistical analysis. By the application of these techniques we have performed a complex, integrative analysis which revealed several new pathogenic pathways. Our study has revealed several potential novel genes and pathways that might have major roles in NB and PCC pathogenesis and progression. The role of Stathmin 1 signaling in the pathogenesis of NB and PCC requires experimental validation to characterize its importance in these tumors. The relevance of PHOX2B gene and protein has not been studied in the pathogenesis of PCC yet, despite having fundamental role in the neural crest-derived precursor cell development. IGF1 signaling in MEN2/NF1-related PCC would also be an interesting topic to investigate. These pathways might even include potential novel therapeutic targets.
This work was supported by the Hungarian Scientific Research Fund (OTKA K100295) and Foundation for Tumorous Children. Miklós Pintér acknowledges the support by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences and grant OTKA.
- Maris JM, Hogarty MD, Bagatell R, Cohn SL: Neuroblastoma. Lancet. 2007, 369: 2106-2120. 10.1016/S0140-6736(07)60983-0.View ArticlePubMedGoogle Scholar
- Mannelli M, Simi L, Gaglianò MS, Opocher G, Ercolino T, Becherini L, Parenti G: Genetics and biology of pheochromocytoma. Exp Clin Endocrinol Diabetes. 2007, 115: 160-165. 10.1055/s-2007-970407.View ArticlePubMedGoogle Scholar
- Neumann HP, Vortmeyer A, Schmidt D, Werner M, Erlic Z, Cascon A, Bausch B, Januszewicz A, Eng C: Evidence of MEN-2 in the original description of classic pheochromocytoma. N Engl J Med. 2007, 357: 1311-1315. 10.1056/NEJMoa071407.View ArticlePubMedGoogle Scholar
- Comino-Méndez I, Gracia-Aznárez FJ, Schiavi F, Landa I, Leandro-García LJ, Letón R, Honrado E, Ramos-Medina R, Caronia D, Pita G, Gómez-Graña A, de Cubas AA, Inglada-Pérez L, Maliszewska A, Taschin E, Bobisse S, Pica G, Loli P, Hernández-Lavado R, Díaz JA, Gómez-Morales M, González-Neira A, Roncador G, Rodríguez-Antona C, Benítez J, Mannelli M, Opocher G, Robledo M, Cascón A: Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet. 2011, 43: 663-667. 10.1038/ng.861.View ArticlePubMedGoogle Scholar
- Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE, Chocron ES, Lechleiter JD, Sass M, Aronin N, Schiavi F, Boaretto F, Opocher G, Toledo RA, Toledo SP, Stiles C, Aguiar RC, Dahia PL: Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet. 2010, 42: 229-233. 10.1038/ng.533.View ArticlePubMedPubMed CentralGoogle Scholar
- Burnichon N, Vescovo L, Amar L, Libé R, de Reynies A, Venisse A, Jouanno E, Laurendeau I, Parfait B, Bertherat J, Plouin PF, Jeunemaitre X, Favier J, Gimenez-Roqueplo AP: Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet. 2011, 20: 3974-3985. 10.1093/hmg/ddr324.View ArticlePubMedGoogle Scholar
- Szabó PM, Tamási V, Molnár V, Andrásfalvy M, Tömböl Z, Farkas R, Kövesdi K, Patócs A, Tóth M, Szalai C, Falus A, Rácz K, Igaz P: Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed. Oncogene. 2010, 29: 3163-3172. 10.1038/onc.2010.80.View ArticlePubMedGoogle Scholar
- Moretti S, Patrone F, Bonassi S: The class of microarray games and the relevance index for genes. Top. 2007, 15: 256-280. 10.1007/s11750-007-0021-4.View ArticleGoogle Scholar
- Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, Seiser E, Jagannathan J, Shusterman S, Bansal M, Khazi D, Winter C, Okawa E, Grant G, Cnaan A, Zhao H, Cheung NK, Gerald W, London W, Matthay KK, Brodeur GM, Maris JM: Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res. 2006, 66: 6050-6062. 10.1158/0008-5472.CAN-05-4618.View ArticlePubMedGoogle Scholar
- Wilzén A, Nilsson S, Sjöberg RM, Kogner P, Martinsson T, Abel F: The Phox2 pathway is differentially expressed in neuroblastoma tumors, but no mutations were found in the candidate tumor suppressor gene PHOX2A. Int J Oncol. 2009, 34: 697-705.PubMedGoogle Scholar
- Albino D, Scaruffi P, Moretti S, Coco S, Truini M, Di Cristofano C, Cavazzana A, Stigliani S, Bonassi S, Tonini GP: Identification of low intratumoral gene expression heterogeneity in neuroblastic tumors by genome-wide expression analysis and game theory. Cancer. 2008, 113: 1412-1422. 10.1002/cncr.23720.View ArticlePubMedGoogle Scholar
- De Preter K, Vandesompele J, Heimann P, Yigit N, Beckman S, Schramm A, Eggert A, Stallings RL, Benoit Y, Renard M, De Paepe A, Laureys G, Påhlman S, Speleman F: Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biol. 2006, 7: R84-10.1186/gb-2006-7-9-r84.View ArticlePubMedPubMed CentralGoogle Scholar
- Hiyama E, Hiyama K, Yamaoka H, Sueda T, Reynolds CP, Yokoyama T: Expression profiling of favorable and unfavorable neuroblastomas. Pediatr Surg Int. 2004, 20: 33-38. 10.1007/s00383-003-1077-3.View ArticlePubMedGoogle Scholar
- Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D, Frebourg T, Michon J, Lyonnet S, Amiel J, Delattre O: Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008, 455: 967-970. 10.1038/nature07398.View ArticlePubMedGoogle Scholar
- Łastowska M, Viprey V, Santibanez-Koref M, Wappler I, Peters H, Cullinane C, Roberts P, Hall AG, Tweddle DA, Pearson AD, Lewis I, Burchill SA, Jackson MS: Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. Oncogene. 2007, 26: 7432-7444. 10.1038/sj.onc.1210552.View ArticlePubMedGoogle Scholar
- Staege MS, Hutter C, Neumann I, Foja S, Hattenhorst UE, Hansen G, Afar D, Burdach SE: DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res. 2004, 64: 8213-8221. 10.1158/0008-5472.CAN-03-4059.View ArticlePubMedGoogle Scholar
- Hensen EF, Goeman JJ, Oosting J, Van der Mey AG, Hogendoorn PC, Cremers CW, Devilee P, Cornelisse CJ: Similar gene expression profiles of sporadic, PGL2-, and SDHD-linked paragangliomas suggest a common pathway to tumorigenesis. BMC Med Genomics. 2009, 2: 25-10.1186/1755-8794-2-25.View ArticlePubMedPubMed CentralGoogle Scholar
- Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti J, Franco D, Bioulac-Sage P, Laurent-Puig P, Zucman-Rossi J: Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007, 45: 42-52. 10.1002/hep.21467.View ArticlePubMedGoogle Scholar
- Corbin M, de Reyniès A, Rickman DS, Berrebi D, Boccon-Gibod L, Cohen-Gogo S, Fabre M, Jaubert F, Faussillon M, Yilmaz F, Sarnacki S, Landman-Parker J, Patte C, Schleiermacher G, Antignac C, Jeanpierre C: WNT/beta-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries?. Genes Chromosomes Cancer. 2009, 48: 816-827. 10.1002/gcc.20686.View ArticlePubMedGoogle Scholar
- Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel PS, Nelson SF: Gene expression profiling of gliomas strongly redicts survival. Cancer Res. 2004, 64: 6503-6510. 10.1158/0008-5472.CAN-04-0452.View ArticlePubMedGoogle Scholar
- Giordano TJ, Au AY, Kuick R, Thomas DG, Rhodes DR, Wilhelm KG, Vinco M, Misek DE, Sanders D, Zhu Z, Ciampi R, Hanash S, Chinnaiyan A, Clifton-Bligh RJ, Robinson BG, Nikiforov YE, Koenig RJ: Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res. 2006, 12: 1983-1993. 10.1158/1078-0432.CCR-05-2039.View ArticlePubMedGoogle Scholar
- Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, McKee M, Gajewski TF: Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009, 69: 3077-3085.View ArticlePubMedGoogle Scholar
- Henderson SR, Guiliano D, Presneau N, McLean S, Frow R, Vujovic S, Anderson J, Sebire N, Whelan J, Athanasou N, Flanagan AM, Boshoff C: A molecular map of mesenchymal tumors. Genome Biol. 2005, 6: R76-10.1186/gb-2005-6-9-r76.View ArticlePubMedPubMed CentralGoogle Scholar
- Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, Jonas D, Libermann TA: Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res. 2005, 11: 5730-5739. 10.1158/1078-0432.CCR-04-2225.View ArticlePubMedGoogle Scholar
- Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT, Christman MF: Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer. 2003, 3: 31-10.1186/1471-2407-3-31.View ArticlePubMedPubMed CentralGoogle Scholar
- Monzon FA, Lyons-Weiler M, Buturovic LJ, Rigl CT, Henner WD, Sciulli C, Dumur CI, Medeiros F, Anderson GG: Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol. 2009, 27: 2503-2508. 10.1200/JCO.2008.17.9762.View ArticlePubMedGoogle Scholar
- Parent AS, Matagne V, Westphal M, Heger S, Ojeda S, Jung H: Gene expression profiling of hypothalamic hamartomas: a search for genes associated with central precocious puberty. Horm Res. 2008, 69: 114-123. 10.1159/000111815.View ArticlePubMedGoogle Scholar
- Su LJ, Chang CW, Wu YC, Chen KC, Lin CJ, Liang SC, Lin CH, Whang-Peng J, Hsu SL, Chen CH, Huang CY: Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. BMC Genomics. 2007, 8: 140-10.1186/1471-2164-8-140.View ArticlePubMedPubMed CentralGoogle Scholar
- Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O: Mesenchymal stem cell features of Ewing tumors. Cancer Cell. 2007, 11: 421-429. 10.1016/j.ccr.2007.02.027.View ArticlePubMedGoogle Scholar
- Wong KK, Chang YM, Tsang YT, Perlaky L, Su J, Adesina A, Armstrong DL, Bhattacharjee M, Dauser R, Blaney SM, Chintagumpala M, Lau CC: Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide microarray reveals two potential subgroups. Cancer Res. 2005, 65: 76-84.PubMedGoogle Scholar
- Schramm A, Schulte JH, Klein-Hitpass L, Havers W, Sieverts H, Berwanger B, Christiansen H, Warnat P, Brors B, Eils J, Eils R, Eggert A: Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene. 2005, 24: 7902-7912. 10.1038/sj.onc.1208936.View ArticlePubMedGoogle Scholar
- López-Jiménez E, Gómez-López G, Leandro-García LJ, Muñoz I, Schiavi F, Montero-Conde C, de Cubas AA, Ramires R, Landa I, Leskelä S, Maliszewska A, Inglada-Pérez L, de la Vega L, Rodríguez-Antona C, Letón R, Bernal C, de Campos JM, Diez-Tascón C, Fraga MF, Boullosa C, Pisano DG, Opocher G, Robledo M, Cascón A: Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol. 2010, 24: 2382-2391. 10.1210/me.2010-0256.View ArticlePubMedGoogle Scholar
- Oberthuer A, Warnat P, Kahlert Y, Westermann F, Spitz R, Brors B, Hero B, Eils R, Schwab M, Berthold F, Fischer M: Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease. Cancer Lett. 2007, 250: 250-267. 10.1016/j.canlet.2006.10.016.View ArticlePubMedGoogle Scholar
- Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A, Hirata T, Kubo H, Goto T, Yamada S, Yoshida Y, Fuchioka M, Ishii S, Nakagawara A: Expression profiling using a tumour-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell. 2005, 7: 337-350. 10.1016/j.ccr.2005.03.019.View ArticlePubMedGoogle Scholar
- Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, Matthay K, Buckley J, Ortega A, Seeger RC: Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst. 2006, 98: 1193-1203. 10.1093/jnci/djj330.View ArticlePubMedGoogle Scholar
- Berwanger B, Hartmann O, Bergmann E, Bernard S, Nielsen D, Krause M, Kartal A, Flynn D, Wiedemeyer R, Schwab M, Schäfer H, Christiansen H, Eilers M: Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell. 2002, 2: 377-386. 10.1016/S1535-6108(02)00179-4.View ArticlePubMedGoogle Scholar
- Brown JL, Snir M, Noushmehr H, Kirby M, Hong SK, Elkahloun AG, Feldman B: Transcriptional profiling of endogenous germ layer precursor cells identifies dusp4 as an essential gene in zebrafish endoderm specification. Proc Natl Acad Sci USA. 2008, 105: 2337-2342. 10.1073/pnas.0708960105.View ArticleGoogle Scholar
- Eisenhofer G, Huynh TT, Pacak K, Brouwers FM, Walther MM, Linehan WM, Munson PJ, Mannelli M, Goldstein DS, Elkahloun AG: Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer. 2004, 11: 897-911. 10.1677/erc.1.00838.View ArticlePubMedGoogle Scholar
- Eisenhofer G, Huynh TT, Elkahloun A, Morris JC, Bratslavsky G, Linehan WM, Zhuang Z, Balgley BM, Lee CS, Mannelli M, Lenders JW, Bornstein SR, Pacak K: Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma. Am J Physiol Endocrinol Metab. 2008, 295: E1223-E1233. 10.1152/ajpendo.90591.2008.View ArticlePubMedPubMed CentralGoogle Scholar
- Fischer M, Bauer T, Oberthür A, Hero B, Theissen J, Ehrich M, Spitz R, Eils R, Westermann F, Brors B, König R, Berthold F: Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q. Oncogene. 2010, 29: 865-875. 10.1038/onc.2009.390.View ArticlePubMedGoogle Scholar
- Huynh TT, Pacak K, Wong DL, Linehan WM, Goldstein DS, Elkahloun AG, Munson PJ, Eisenhofer G: Transcriptional regulation of phenylethanolamine N-methyltransferase in pheochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Ann N Y Acad Sci. 2006, 1073: 241-252. 10.1196/annals.1353.026.View ArticlePubMedGoogle Scholar
- Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, König R, Haas S, Eils R, Schwab M, Brors B, Westermann F, Fischer M: Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol. 2006, 24: 5070-5078. 10.1200/JCO.2006.06.1879.View ArticlePubMedGoogle Scholar
- Takita J, Ishii M, Tsutsumi S, Tanaka Y, Kato K, Toyoda Y, Hanada R, Yamamoto K, Hayashi Y, Aburatani H: Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma. Genes Chromosomes Cancer. 2004, 40: 120-132. 10.1002/gcc.20021.View ArticlePubMedGoogle Scholar
- Thorell K, Bergman A, Carén H, Nilsson S, Kogner P, Martinsson T, Abel F: Verification of genes differentially expressed in neuroblastoma tumours: a study of potential tumour suppressor genes. BMC Med Genomics. 2009, 2: 53-10.1186/1755-8794-2-53.View ArticlePubMedPubMed CentralGoogle Scholar
- Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, Swerts K, Bravo S, Scaruffi P, Tonini GP, De Bernardi B, Noguera R, Piqueras M, Cañete A, Castel V, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Michon J, Combaret V, Fischer M, Oberthuer A, Ambros PF, Beiske K, Bénard J, Marques B, Rubie H, Kohler J, Pötschger U, Ladenstein R, Hogarty MD, McGrady P, London WB, Laureys G, Speleman F, Vandesompele J: Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol. 2009, 10: 663-671. 10.1016/S1470-2045(09)70154-8.View ArticlePubMedPubMed CentralGoogle Scholar
- Schulte JH, Schowe B, Mestdagh P, Kaderali L, Kalaghatgi P, Schlierf S, Vermeulen J, Brockmeyer B, Pajtler K, Thor T, de Preter K, Speleman F, Morik K, Eggert A, Vandesompele J, Schramm A: Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int J Cancer. 2010, 127: 2374-2385. 10.1002/ijc.25436.View ArticlePubMedGoogle Scholar
- Tömböl Z, Eder K, Kovács A, Szabó PM, Kulka J, Likó I, Zalatnai A, Rácz G, Tóth M, Patócs A, Falus A, Rácz K, Igaz P: MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas. Mod Pathol. 2010, 23: 1583-1595. 10.1038/modpathol.2010.164.View ArticlePubMedGoogle Scholar
- Cheng WC, Chang CW, Chen CR, Tsai ML, Shu WY, Li CY, Hsu IC: Identification of reference genes across physiological states for qRT-PCR through microarray meta-analysis. PLoS One. 2011, 6: e17347-10.1371/journal.pone.0017347.View ArticlePubMedPubMed CentralGoogle Scholar
- Shapley LS: A Value for n-Person Games. Contributions to the Theory of Games Volume II (Annals of Mathematical Studies 28). Edited by: Kuhn HW, Tucker AW. 1953, Princeton: Princeton University Press, 307-317.Google Scholar
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005, 102: 15545-15550. 10.1073/pnas.0506580102.View ArticlePubMedPubMed CentralGoogle Scholar
- Martini P, Risso D, Sales G, Romualdi C, Lanfranchi G, Cagnin S: Statistical Test of Expression Pattern (STEPath): a new strategy to integrate gene expression data with genomic information in individual and meta-analysis studies. BMC Bioinformatics. 2011, 12: 92-10.1186/1471-2105-12-92.View ArticlePubMedPubMed CentralGoogle Scholar
- Tömböl Z, Szabó PM, Molnár V, Wiener Z, Tölgyesi G, Horányi J, Riesz P, Reismann P, Patócs A, Likó I, Gaillard RC, Falus A, Rácz K, Igaz P: Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocr Relat Cancer. 2009, 16: 895-906. 10.1677/ERC-09-0096.View ArticlePubMedGoogle Scholar
- Huber K, Karch N, Ernsberger U, Goridis C, Unsicker K: The role of Phox2B in chromaffin cell development. Dev Biol. 2005, 279: 501-508. 10.1016/j.ydbio.2005.01.007.View ArticlePubMedGoogle Scholar
- Mosse YP, Laudenslager M, Khazi D, Carlisle AJ, Winter CL, Rappaport E, Maris JM: Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet. 2004, 75: 727-730. 10.1086/424530.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhu J, Garcia-Barcelo MM, Tam PK, Lui VC: HOXB5 cooperates with NKX2-1 in the transcription of human RET. PLoS One. 2011, 6: e20815-10.1371/journal.pone.0020815.View ArticlePubMedPubMed CentralGoogle Scholar
- Rychlik JL, Hsieh M, Eiden LE, Lewis EJ: Phox2 and dHAND transcription factors select shared and unique target genes in the noradrenergic cell type. J Mol Neurosci. 2005, 27: 281-292. 10.1385/JMN:27:3:281.View ArticlePubMedGoogle Scholar
- Margetts CD, Astuti D, Gentle DC, Cooper WN, Cascon A, Catchpoole D, Robledo M, Neumann HP, Latif F, Maher ER: Epigenetic analysis of HIC1, CASP8, FLIP, TSP1, DCR1, DCR2, DR4, DR5, KvDMR1, H19 and preferential 11p15.5 maternal-allele loss in von Hippel-Lindau and sporadic phaeochromocytomas. Endocr Relat Cancer. 2005, 12: 161-172. 10.1677/erc.1.00865.View ArticlePubMedGoogle Scholar
- Poulaki V, Mitsiades N, Romero ME, Tsokos M: Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2. Cancer Res. 2001, 61: 4864-4872.PubMedGoogle Scholar
- Mah SP, Zhong LT, Liu Y, Roghani A, Edwards RH, Bredesen DE: The protooncogene bcl-2 inhibits apoptosis in PC12 cells. J Neurochem. 1993, 60: 1183-1186. 10.1111/j.1471-4159.1993.tb03275.x.View ArticlePubMedGoogle Scholar
- Okawa ER, Gotoh T, Manne J, Igarashi J, Fujita T, Silverman KA, Xhao H, Mosse YP, White PS, Brodeur GM: Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene. 2008, 27: 803-810. 10.1038/sj.onc.1210675.View ArticlePubMedGoogle Scholar
- Aarts M, Dannenberg H, DeLeeuw RJ, van Nederveen FH, Verhofstad AA, Lenders JW, Dinjens WN, Speel EJ, Lam WL, de Krijger RR: Microarray-based CGH of sporadic and syndrome-related pheochromocytomas using a 0.1-0.2 Mb bacterial artificial chromosome array spanning chromosome arm 1p. Genes Chromosomes Cancer. 2006, 45: 83-93. 10.1002/gcc.20268.View ArticlePubMedGoogle Scholar
- Björklund P, Cupisti K, Fryknäs M, Isaksson A, Willenberg HS, Akerström G, Hellman P, Westin G: Stathmin as a marker for malignancy in pheochromocytomas. Exp Clin Endocrinol Diabetes. 2010, 118: 27-30. 10.1055/s-0029-1202789.View ArticlePubMedGoogle Scholar
- Sadow PM, Rumilla KM, Erickson LA, Lloyd RV: Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors. Endocr Pathol. 2008, 19: 97-103. 10.1007/s12022-008-9028-0.View ArticlePubMedGoogle Scholar
- Cassimeris L: The oncoprotein 18/stathmin family of microtubule destabilizers. Curr Opin Cell Biol. 2002, 14: 18-24. 10.1016/S0955-0674(01)00289-7.View ArticlePubMedGoogle Scholar
- Don S, Verrills NM, Liaw TY, Liu ML, Norris MD, Haber M, Kavallaris M: Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs. Mol Cancer Ther. 2004, 3: 1137-1146. 10.4161/cbt.3.11.1216.View ArticlePubMedGoogle Scholar
- Bashaw GJ, Klein R: Signaling from axon guidance receptors. Cold Spring Harb Perspect Biol. 2010, 2: a001941-10.1101/cshperspect.a001941.View ArticlePubMedPubMed CentralGoogle Scholar
- Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR, Light JE, Kolla V, Evans AE: Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res. 2009, 15: 3244-3250. 10.1158/1078-0432.CCR-08-1815.View ArticlePubMedPubMed CentralGoogle Scholar
- Lazova R, Gould Rothberg BE, Rimm D, Scott G: The semaphorin 7A receptor Plexin C1 is lost during melanoma metastasis. Am J Dermatopathol. 2009, 31: 177-181. 10.1097/DAD.0b013e318196672d.View ArticlePubMedGoogle Scholar
- Grimberg A, Cohen P: Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 2000, 183: 1-9. 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J.View ArticlePubMedPubMed CentralGoogle Scholar
- Yu Y, Gao Y, Qin J, Kuang CY, Song MB, Yu SY, Cui B, Chen JF, Huang L: CCN1 promotes the differentiation of endothelial progenitor cells and reendothelialization in the early phase after vascular injury. Basic Res Cardiol. 2010, 105: 713-724. 10.1007/s00395-010-0117-0.View ArticlePubMedGoogle Scholar
- Kawai K, Iwashita T, Murakami H, Hiraiwa N, Yoshiki A, Kusakabe M, Ono K, Iida K, Nakayama A, Takahashi M: Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation. Cancer Res. 2000, 60: 5254-5260.PubMedGoogle Scholar
- Lui WO, Chen J, Gläsker S, Bender BU, Madura C, Khoo SK, Kort E, Larsson C, Neumann HP, Teh BT: Selective loss of chromosome 11 in pheochromocytomas associated with the VHL syndrome. Oncogene. 2002, 21: 1117-1122. 10.1038/sj.onc.1205149.View ArticlePubMedGoogle Scholar
- Kaelin WG: Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002, 2: 673-682. 10.1038/nrc885.View ArticlePubMedGoogle Scholar
- Van Nederveen FH, Korpershoek E, DeLeeuw RJ, Verhofstad AA, Lenders JW, Dinjens WN, Lam WL, de Krijger RR: Array-comparative genomic hybridization in sporadic benign pheochromocytomas. Endocr Relat Cancer. 2009, 16: 505-513. 10.1677/ERC-08-0241.View ArticlePubMedGoogle Scholar
- Favier J, Brière JJ, Burnichon N, Rivière J, Vescovo L, Benit P, Giscos-Douriez I, De Reyniès A, Bertherat J, Badoual C, Tissier F, Amar L, Libé R, Plouin PF, Jeunemaitre X, Rustin P, Gimenez-Roqueplo AP: The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS One. 2009, 4: e7094-10.1371/journal.pone.0007094.View ArticlePubMedPubMed CentralGoogle Scholar
- Gross DJ, Reibstein I, Weiss L, Slavin S, Dafni H, Neeman M, Pines M, Nagler A: Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo. Clin Cancer Res. 2003, 9: 3788-3793.PubMedGoogle Scholar
- Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG: Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001, 7: 575-583. 10.1038/87904.View ArticlePubMedGoogle Scholar
- Ribatti D: The controversial role of placental growth factor in tumor growth. Cancer Lett. 2011, 307: 1-5. 10.1016/j.canlet.2011.02.043.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1755-8794/5/48/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.